Cleveland
Cleveland Clinic |
Funded |
Generated |
|
---|---|---|---|
MATTHEW K SUMMERS, PHD The role of p31comet in breast cancer progression and therapy |
[Breast Cancer] 2012 |
$60,000 |
$1,194,463 |
JUSTIN D LATHIA, PHD Targeting CXCR7 mediated vascular interactions in Glioblastoma |
[Breast Cancer] 2012 |
$60,000 |
$9,376,641 |
TAO LU, PHD Study the role of FBXL 11 protein in colitis associated cancer (CAC). |
[Colon cancer] 2010 |
$60,000 |
|
LAN ZHOU, MD, PHD The Role of Aberrant Notch Signaling in the Chronic Myeloproliferative Disorder Induced by Fucosylation Deficiency |
[Leukemia] 2007 |
$50,000 |
$636,795 |
MALACHI MIXON III Restricted gift (grant) for cancer research |
[Special Gift] 2007 |
$10,000 |
|
PATRICK C MA MD High-Throughput Cell-Based MET Inhibitor Development For Lung Cancer Individualized Therapy |
[Lung Cancer] 2006 |
$50,000 |
$1,342,660 |
MARIE-ODILE PARAT, PHAR, MD, PHD Role of Caveolin-1 in H-Ras Targeting |
[Molecular Genetics] 2005 |
$50,000 |
$750,000 |
MARINA ANTOCH, PHD Diagnostic Markers Of Mammalian Circadian Clock Function |
[Cancer Therapy] 2002 |
$50,000 |
$1,676,250 |
NYWANA SIZEMORE, PHD Molecular Targets Of The PI3K/AKT/IKK Pathway In Breast Cancer |
[Breast Cancer] 2002 |
$49,500 |
$1,004,824 |
MICHAEL A VOGELBAUM, MD, PHD Regulation of Apoptosis in Glioma Primary Cell Cultures |
[Brain Cancer] 2001 |
$50,000 |
|
MUNNA AGARWAL, PHD Identification of molecular components involved in regulation of p53 function |
[Gene Mutation] 1999 |
$50,000 |
|
CHRISTINE CAMPBELL, PHD Role of the T-box genes, TBX2 and TBX3, in breast carcinoma |
[Breast Cancer] 1997 |
$40,000 |
|
SIPRA BANERJEE, PHD Genomic Instability in Familial Breast Cancer |
[Breast Cancer] 1995 |
$40,000 |
$306,675 |
TOTAL: |
$619,500 |
$16,288,308 |
Case Western Reserve University |
Funded |
Generated |
|
---|---|---|---|
VINAY VARADAN, PhD lmmunosuppressive mechanisms and response prediction in HER2+ early breast cancer |
[Breast Cancer] 2016 |
$60,000 |
|
HUIPING LIU, MD, PHD Targeting IL-11 in breast tumor initating cell-mediated metastasis |
[Breast Cancer] 2015 |
$60,000 |
|
EFSTATHIOS KARATHANASIS, PHD Treatment of cancer metastasis using a multicomponent nanoparticle |
[Chemotherapy Treatment] 2013 |
$60,000 |
$2,820,000 |
NICOLE FRANZISKA STEINMETZ, PHD A Novel Plant Viral Nanoparticle Drug Delivery System for Treatment of Aggressive HER2+ Breast Cancer |
[Breast Cancer] 2012 |
$60,000 |
$1,040,000 |
BARBARA BEDOGNI, PHD Dissecting the role of the Notch signaling pathway in melanoma metastasis |
[Skin Cancer] 2010 |
$60,000 |
$1,585,209 |
DAVID WALD, MD, PHD Characterization of a novel pathway to selectively target AML cells |
[Leukemia] 2010 |
$60,000 |
$1,994,201 |
SCOTT M WELFORD, PHD The impact of tissue hypoxia on tumor initiation |
[Radiation Oncology/Renal Cancer]< br/>2010 |
$60,000 |
|
HORST VON RECUM, PHD Multiplexing Molecular Interactions to Improve Chemotherapeutic Delivery |
[Chemotherapy] 2008 |
$50,000 |
$517,450 |
YANWU YANG, PHD Structural Mechanism of How SnoN-FHL2 Complex Activates Wnt/beta-catenin Signaling |
[Tumor Research] 2007 |
$50,000 |
|
ZHILIN HU, PHD Bronchoscopic OCT imaging to identify premalignant changes in the pulmonary epithelium |
[Lung Cancer] 2006 |
$49,996 |
|
MATTHIAS BUCK, Phd cMet/Eph Phosphorylation of Small GTPases and their Role in Cancer |
[Molecular Genetics] 2006 |
$49,981 |
$100,000 |
HUA LOU, PHD Medullary Thyroid Carcinoma As A Model To Study Alternative RNA Splicing |
[Thyroid Cancer] 2002 |
$41,830 |
$3,747,896 |
NARENDRA NARAYANA, PHD Crystal Structure Determination of DSX-DNA Complex |
[Leukemia] 2002 |
$25,000 |
|
HUNG-YING KAO, PHD The Role Of GPS2 In Transcriptional Co-Repressor SMRT-Mediated Repression |
[Leukemia] 2002 |
$50,000 |
$1,729,846 |
ZHONGWU GUO, PHD Glycoengineering Cancer Cells for Selective Immunotargeting of Cancer |
[Molecular Genetics] 2001 |
$50,000 |
$2,859,484 |
NIHAL AHMAD, PHD Role of Ornithine Decarboxylase in Phtotcarcinogenesis |
[Skin and Prostate Cancer] 2001 |
$25,000 |
|
NIHAL AHMAD, PHD Resveratrol in Prevention of Cancer |
[Skin and Prostate Cancer] 1999 |
$50,000 |
$2,903,763 |
SANTOSH KATIYAR, PHD UV-induced oxidative stress-mediated human skin cancer, and prevention by antioxidants |
[Skin Cancer] 1999 |
$50,000 |
$2,462,935 |
DAVID DANIELPOUR, PHD Regulation of TGF-beta signal transduction by IGF-in prostatic cells |
[Prostate Cancer] 1999 |
$50,000 |
$4,274,659 |
MONICA MONTANO, PHD Estrogen Receptor-Selective Coactivators in Breast Cancer Cells |
[Breast Cancer] 1999 |
$50,000 |
$3,130,875 |
ANTONIO GUALBERTO, MD Altered Mitotic Checkpoint in p53 mutant cells |
[Gene Mutation] 1999 |
$9,662 |
|
RAJESH AGARWAL, PHD Antioxidants and Prostate Cancer Chemoprevention |
[Prostate Cancer] 1997 |
$40,000 |
$5,769,264 |
ELLEN RORKE, PHD Epidermal Growth Factor in Human Cervical Cancer |
[Cervical Cancer] 1995 |
$40,000 |
|
PHILIP PAUL GARNER, PHD The Development of Novel Oligonucleotide Surrogates |
[Gene Mutation] 1994 |
$40,000 |
$441,504 |
SANFORD MARKOWITZ, MD, PHD Novel Markers of Colon Cancer Progression and Prognosis |
[Colon Cancer] 1994 |
$40,000 |
$6,040,281 |
CLARK W DISTELHORST, MD Steroid Receptor Nuclear Uptake Mechanism |
[Hormone Therapy] 1993 |
$39,753 |
$7,980,830 |
TOTAL: |
$1,220,222 |
$49,398,197 |
Metrohealth Medical Center |
Funded |
Generated |
|
---|---|---|---|
ARUNA BASU, PHD Functional Analysis of LKB1 Gene Linked to Peutz-Jeghers Syndrome |
[Pancreatic Cancer] 2010 |
$49,848 |
$251,000 |
SUBRATA HALDAR, PHD Epigenetic Inactivation of Apaf-1 in Metastatic Melanoma |
[Skin Cancer] 2002 |
$49,996 |
|
BRUCE AVERBOOK, MD FASC Brain Tumor Immunosuppression of Tumor Draining Lymph Node Antitumor |
[Brain Cancer] 1997 |
$40,000 |
|
TOTAL: |
$139,844 |
$251,000 |